Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0109)

Montreal, Quebec H2X 3E4

0 studies enrolling now · 1 studies all time

What they study most

Metastatic Hormone-Sensitive Prostate Cancer

Studies at this site

• Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991) — Completed